Business Information
The company's principal activity is to develop, produce, license and distribute autologous cellular therapies for the treatment of chronic non-healing wounds. The company's proprietary wound care product line is based on its branded product, autologel. This product contains autologous multiple growth factors, platelet membranes, fibrin matrix scaffold and acts as a bioactive sealant. The entire process is called autologeltm system, which begins with drawing one to six small tubes (5-30 cc) of the patient's blood through a standard blood-draw procedure. Platelet rich plasma is separated from the whole blood through centrifugation using a specially calibrated tabletop-sized centrifuge. The separated platelet rich plasma is then mixed with reagents, which, upon agitation, process the liquid into a gel. The company markets autologel into the chronic wound care market through the sale of disposable kits that provide single treatment for wound application.
|
|
Name |
Title
|
Email
|
| Kshitij Mohan | Chmn., CEO | N/A | | Andrew Maslan | CFO | N/A | | Carelyn Fylling | VP - Professional Services | N/A | | David Hotchkiss | VP - Sales, Marketing | N/A | | Arun Deva | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,948 | (2,263) | | 2005 | 1,514 | (6,503) | | 2004 | 1,146 | (8,139)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
